360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Zytiga

Type: Product

Name: Zytiga

First reported 17 hours ago - Updated 16 hours ago - 2 reports

Johnson & Johnson

Johnson & Johnson Gets Key Cancer Drug With Aragon Buy

Tickers in this article: JNJ MDVNNEW YORK (TheStreet) -- The last time I talked about health care giant Johnson & Johnson I said the stock looked "too healthy".Aside from concerns about the company's valuation, I didn't feel comfortable about Johnson ... [Published AdvisorSource.com - 16 hours ago]

Entities: Johnson & Johnson, Aragon Pharmaceuticals Inc, Medivation Inc

First reported 17 hours ago - Updated 17 hours ago - 1 reports

Medivation’s Xtandi Threatened by J&J’s New Acquisition

One of the biotech laggards of the year, Medivation (NASDAQ: MDVN) saw a very high volume selloff (-6.78% ▼$47.41/share) yesterday after rival Johnson & Johnson (NYSE: JNJ) announced the acquisition of Aragon Pharmaceuticals – a company that was developing ... [Published BioMedReports - 17 hours ago]

Entities: Xtandi, Medivation Inc, Johnson & Johnson, Zytiga

First reported Jun 17 2013 - Updated 17 hours ago - 5 reports

J&J expands pipeline in prostate cancer

Johnson & Johnson is lining up prostate-cancer drug contenders. The multidisciplinary behemoth announced Monday that it was buying up Aragon Pharmaceutical's experimental androgen receptor antagonist ARN-502 for $650 million up-front and up to $350 million ... [Published Medical Marketing And Media - Jun 18 2013]

Entities: Johnson & Johnson, Prostate Cancer, external radiation, internal radiation

First reported Jun 17 2013 - Updated 20 hours ago - 8 reports

J&J acquires oncology candidate in $1bn Aragon buy

ARN-509 is in phase II development for Johnson & Johnson (J&J) yesterday gained the rights to a promising prostate cancer candidate by acquiring oncology specialists Aragon Pharmaceuticals. J&J has high hopes for Aragon's lead candidate ARN-509, which ... [Published PMLive - 21 hours ago]

Entities: Aragon Pharmaceuticals Inc, Johnson & Johnson, Zytiga, Oncology, Androgen

First reported Jun 18 2013 - Updated Jun 18 2013 - 2 reports

J&J Buys Aragon Boosting Prostate Cancer Franchise Beyond Zytiga

Home » Blogs » J&J Buys Aragon, Boosting Prostate Cancer Franchise Beyond ZytigaThe buyout gives J&J Aragon’s androgen receptor inhibitor similar to Medivation’s Xtandi, a potential blockbuster and competitor. In the process, Aragon’s investors will back ... [Published BioPortfolio - Jun 18 2013]

Entities: Zytiga, Prostate Cancer, Biotechnology, Xtandi, Medivation Inc

First reported Jun 17 2013 - Updated Jun 18 2013 - 2 reports

UPDATE 2-JJ in $1 bln deal to bolster prostate-cancer focus

June 17 (Reuters) - Johnson & Johnson said it would pay up to $1 billion for Aragon Pharmaceuticals and its experimental drugs for prostate cancer, to bolster J&J's role in the field after it acquired another experimental prostate-cancer treatment four ... [Published Big News Network - Jun 18 2013]

Entities: Zytiga, Johnson & Johnson, Prostate Cancer, Cougar Biotechnology Inc, Patient

First reported Jun 05 2013 - Updated Jun 05 2013 - 1 reports

Janssen receives Health Canada approval for prostate cancer drug

Janssen Inc., a pharmaceutical company, has received Health Canada approval for the once-daily, oral medication ZYTIGA, for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer, or mCRPC, in patients ... [Published Individual.com - Jun 05 2013]

Entities: Zytiga, Health Canada, Prednisone

First reported May 30 2013 - Updated May 30 2013 - 1 reports

Medivation, Inc. Presents at 38th Annual Deutsche Bank Health Care Conference, May-29-2013 04:50 PM

Andrew CallawayHi, good afternoon. Thanks for joining us for the last session of the day. I'm here with David Hung from Medivation. I'm Andrew Callaway, I'm the global head of life sciences on the investment banking side and happy to be here for this ... [Published Seeking Alpha - May 30 2013]

Entities: Zytiga, Xtandi, Medivation Inc

First reported May 29 2013 - Updated May 29 2013 - 1 reports

Health Canada expands indication for ZYTIGAÂ®* in men with metastatic prostate cancer

(CNW Group) ~New indication provides physicians with option to be used earlier in treatment of the disease, with hope of delaying chemotherapy~ Janssen Inc. announced today that Health Canada has approved the once-daily, oral medication ZYTIGA(Â®) ... [Published Individual.com - May 29 2013]

Entities: Health Canada, Metastatic, Prostate Cancer

First reported May 23 2013 - Updated May 24 2013 - 2 reports

J&J sees 10 new products by 2017

says it is looking to have ten new pharma products on the market in the next four years as it looks to build on a strong 2012.Speaking at an analysts’ meeting this week, the firm said its ten new medicines include: simeprevir for hepatitis C; ibrutinib ... [Published Pharma Times - May 24 2013]

Entities: Johnson & Johnson, IMS Health Inc, Emerging Markets, Ibrutinib

First reported May 23 2013 - Updated May 23 2013 - 2 reports

Johnson & Johnson Is Going Big With New Meds

The world’s biggest maker of healthcare products, Johnson & Johnson ( NYSE:JNJ ) is ready to prove itself again. With its status as fastest growing pharmaceutical business in 2012, it doesn’t come as a surprise that the drugmaker has big plans for the ... [Published Wall St. Cheat Sheet - May 23 2013]

Entities: Johnson & Johnson, Paul Stoffels, blood thinner, Xarelto, Zytiga

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Medivation, Inc. Presents at UBS Global Healthcare Conference, May-20-2013 01:00 PM

Matthew Roden - UBS Investment Bank, Research DivisionGood afternoon, everyone. My name is Matt Roden. I'm one the biopic analysts here at UBS. I'd like to thank everyone for attending the new UBS Global Healthcare Conference. I'm pleased and privileged ... [Published Seeking Alpha - May 20 2013]

Entities: Xtandi, Patient, Placebo, Medivation Inc

Quotes

"Companies like Medivation -- which has a strong oral medication drug that rivals Zytiga -- should not be taken lightly. This is where JNJ's extraordinarily well-diversified business should offset potential near-term headwinds."

Johnson & Johnson Gets Key Cancer Drug With Aragon Buy [Published AdvisorSource.com - 16 hours ago]

Tuttle said the findings will likely "open a whole new field for how we replace these 21-hydroxylase patients."

Prostate Cancer Tx May Solve Cortisol Deficit [Published MedPage Today - 18 hours ago]

...Peter F Lebowitz, global therapeutic area head, oncology for J&J's JanssenJanssen research and development unit said, "ARN-509 complements Zytiga and provides the potential for exciting, novel approaches to treat prostate cancer patients. Prostate cancer is one of our main areas of focus."

US stock market daily report (June 17, 2013, Monday) [Published Stock Markets Review - Jun 18 2013]

...between biotech and pharma and will provide an optimal outcome for the ARN-509 program and the prostate cancer patient community," Heyman said. "The Aragon team is passionate about bringing game-changing therapies to cancer patients and is excited to have carry forward this innovative prostate cancer treatment. is clearly a recognized leader in the oncology field, and their development and commercial capabilities in the prostate cancer area are unparalleled."

Johnson & Johnson makes deal to buy Aragon Pharmaceuticals for as much as $1 billion [Published Drug Discovery News - Jun 18 2013]

More Content

sort by: Date \| Relevance
JPMorgan Names Co-Chiefs For UK Investment Bank... [Published Wall St. Cheat Sheet - 9 hours ago]
JPMorgan Names Co-Chiefs For UK Investment Bank... [Published Wall St. Cheat Sheet - 10 hours ago]
Johnson & Johnson Gets Key Cancer Drug With Ara... [Published AdvisorSource.com - 16 hours ago]
An Interview With Elemer Piros: A Strong Year F... [Published Seeking Alpha - 17 hours ago]
Johnson & Johnson Gets Key Cancer Drug With Ara... [Published The Street Latest - 17 hours ago]
Medivation’s Xtandi Threatened by J&J’s New Acq... [Published BioMedReports - 17 hours ago]
J&J to Buy Aragon for $1 Billion Zacks [Published Yahoo! Finance - 17 hours ago]
Prostate Cancer Tx May Solve Cortisol Deficit [Published MedPage Today - 18 hours ago]
J&J acquires oncology candidate in $1bn Aragon buy [Published PMLive - 21 hours ago]
US stock market daily report (June 17, 2013, Mo... [Published Stock Markets Review - Jun 18 2013]
J&J Buys Aragon Boosting Prostate Cancer Franch... [Published BioPortfolio - Jun 18 2013]
Johnson & Johnson makes deal to buy Aragon Phar... [Published Drug Discovery News - Jun 18 2013]
Johnson & Johnson And Aragon May Have Medivatio... [Published Citybizlist - Jun 18 2013]
J&J expands pipeline in prostate cancer [Published Medical Marketing And Media - Jun 18 2013]
J&J Buys Aragon, Boosting Prostate Cancer Franc... [Published The Rose Sheet - Jun 18 2013]
UPDATE 2-JJ in $1 bln deal to bolster prostate-... [Published Big News Network - Jun 18 2013]
Evening Business News digest [Published Delaware Online - Jun 18 2013]
JJ adds to Zytiga with Aragons prostate cancer ... [Published Big News Network - Jun 18 2013]
J&J adds to Zytiga with Aragon's prostate cance... [Published Pharma Times - Jun 17 2013]
J&J deal not negative for Medivation, says Citi... [Published Yahoo! Finance - Jun 17 2013]
Johnson & Johnson And Aragon May Have Medivatio... [Published Seeking Alpha - Jun 17 2013]
Markets Higher Closing News 6/17/13. [Published Euronext - Jun 17 2013]
J&J To Acquire Aragon [Published Contract Pharma - Jun 17 2013]
Medivation dips as J&J buys Aragon Pharma [Published CNBC - Jun 17 2013]
Johnson & Johnson to Buy Aragon Pharmaceuticals... [Published Motley Fool - Jun 17 2013]
Johnson & Johnson to Buy Aragon Pharmaceuticals... [Published Motley Fool Discussion Boards - Jun 17 2013]
Boeing to Upgrade French AWACS and 2 Other Dow ... [Published Wall St. Cheat Sheet - Jun 17 2013]
Boeing to Upgrade French AWACS and 2 Other Dow ... [Published Wall St. Cheat Sheet - Jun 17 2013]
Johnson & Johnson to buy Aragon Pharmaceuticals [Published Manufacturing Chemist - Jun 17 2013]
J&J, in new $1 billion deal, bolsters prostate-... [Published NewsRT.co.uk - Jun 17 2013]

Blogs

sort by: Date \| Relevance
JPMorgan Names Co-Chiefs For UK Investment Bank... [Published Wall St. Cheat Sheet - 9 hours ago] JPMorgan Chase & Co. ( NYSE : JPM ): Current price $ 54.11A memo obtained by Bloomberg News indicates that JPMorgan has named Ina De and Conor Hillery as co-chiefs of its United Kingdom investment banking business . De , who is currently the co-head of ...
JPMorgan Names Co-Chiefs For UK Investment Bank... [Published Wall St. Cheat Sheet - 10 hours ago] JPMorgan Chase & Co. ( NYSE:JPM ): Current price $54.11 A memo obtained by Bloomberg News indicates that JPMorgan has named Ina De and Conor Hillery as co-chiefs of its United Kingdom investment banking business . De, who is currently the co-head ...
Boeing to Upgrade French AWACS and 2 Other Dow ... [Published Wall St. Cheat Sheet - Jun 17 2013] The Boeing Company ( NYSE:BA ): Current price $103.34On Monday, Boeing reported that it has been awarded a contract valued at $354 million, for a major upgrade to four French E-3F Airborne Warning and Control System (AWACS) aircraft. The upgrade will ...
Boeing to Upgrade French AWACS and 2 Other Dow ... [Published Wall St. Cheat Sheet - Jun 17 2013] The Boeing Company ( NYSE:BA ): Current price $103.34 On Monday, Boeing reported that it has been awarded a contract valued at $354 million, for a major upgrade to four French E-3F Airborne Warning and Control System (AWACS) aircraft. The upgrade will ...
J&J: Adding Another Pearl to its Acquisition Ne... [Published Wall St. Cheat Sheet - Jun 17 2013] Johnson & Johnson ( NYSE:JNJ ) announced Monday that it would buy privately-held Aragon Pharmaceuticals for as much as $1 billion .Like many major pharmaceutical manufacturers, including Pfizer ( NYSE:PFE ) and AstraZeneca ( NYSE:AZN ), Johnson & Johnson ...

Press Releases

sort by: Date \| Relevance
Health Canada expands indication for ZYTIGA®* i... [Published PR Newswire - May 29 2013]
Johnson & Johnson Pharmaceuticals Segment Poise... [Published PR Newswire - May 23 2013]
Janssen Oncology Data to be Presented at 2013 A... [Published PR Newswire: General Business - May 15 2013]
Despite the Recent Availability of Xtandi, Zyti... [Published PR Newswire: Health - Mar 25 2013]
Research and Markets: Xgeva (Prostate Cancer) -... [Published Business Wire Health News - Mar 20 2013]